Chester County News and Community Website
NORRISTOWN, PA — MRO has acquired Clinetic, a fast-growing recruitment management platform that uses artificial intelligence to help hospitals and life sciences companies identify, screen and enroll clinical trial participants …
MRO’s Bold Bet on AI Sparks New Race to Speed Up U.S. Clinical Trials Read More
MALVERN, PA — YPrime unveiled new research showing that artificial intelligence can dramatically reduce human error and accelerate global clinical trial startup, cutting eCOA localization review cycles by two-thirds and …
AI Breakthrough Promises Faster, Cleaner Clinical Trials in Stunning New YPrime Study Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may reverse cognitive decline in Parkinson’s disease patients who also exhibit Alzheimer’s-related amyloid …
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a federal priority-review request for its investigational SkinJect microneedle patch, a dissolvable doxorubicin-based therapy designed to non-invasively treat basal cell …
Skin Cancer Breakthrough? Pharma Firm Seeks Fast-Track FDA Voucher for Novel Patch Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported third-quarter 2025 results and detailed a series of regulatory and clinical milestones that could reshape the company’s trajectory as it moves closer …
INOVIO Advances Toward First Commercial Product as BLA Filing Caps Pivotal Quarter Read More
HORSHAM, PA — OrtoWay-US Inc., a U.S.–German MedTech company specializing in precision spinal surgery tools, has released results from the first prospective, multi-center clinical study evaluating its OrtoWell® Distractor System …
New Study Shows Hydraulic Spine Tool Could Redefine Safety Standards in Surgery Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third quarter 2025 financial results and released new analyses showing sustained, long-term therapeutic benefit from its chronic hepatitis B candidate imdusiran …
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) reported third quarter 2025 financial results and highlighted steady momentum across its antiviral programs, including Phase 2 progress for its COVID candidate …
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, citing emerging signs of …
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported third-quarter 2025 financial results and detailed a series of clinical, operational, and intellectual-property developments that the company says position its lead …
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise Read More